Catridecacog

Catridecacog (brand name Tretten in the US and NovoThirteen in Europe) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.

单词	Catridecacog
释义	Catridecacog 英语百科 Catridecacog Catridecacog (brand name Tretten in the US and NovoThirteen in Europe) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.
随便看	hardware resource hardware resource control hardware resources hardware resource utilization Hardware restriction hardware saturation hardware scheduler hardware security hardware select hardware selection criteria hardware selector Hardware sensor hardware service ability ratio hardware serviceability ratio Hardware shop hardware simulation technique hardware simulator hardwaresoftware changeover hardware sorter hardware source hardware specification sheet hardware speedup hardware spending hardware sprite hardware stack